Transgenic ungulates having reduced prion protein activity and uses thereof
AssigneeKirin Holdings Kabushiki Kaisha
InventorsJames Robl, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida
Life of this patent
Estimating the term…
Loading patent…
AssigneeKirin Holdings Kabushiki Kaisha
InventorsJames Robl, Yoshimi Kuroiwa, Kazuma Tomizuka, Isao Ishida
Estimating the term…
The invention provides cloned transgenic ungulates (e.g., bovines) in which prion protein activity is reduced by one or more genetically engineered mutations. Desirably, these transgenic bovines are also genetically modified to express xenogenous (e.g., human) antibodies. Because of their resistance to prion-related diseases such as bovine spongiform encephalopy (also known as mad cow disease), these bovines are a safer source of human antibodies for pharmaceutical uses and a safer source of agricultural products.
A bovine comprising a non-naturally occurring mutation in one or both alleles of an endogenous prion nucleic acid
A bovine cell comprising a non-naturally occurring mutation in one or both alleles of an endogenous prion nucleic acid.
A method for producing a transgenic bovine cell having reduced expression of functional prion protein, comprising introducing a first prion gene targeting vector into a bovine cell under conditions that allow homologous recombination between said first vector and a first allele of an endogenous prion nucleic acid in said cell, thereby introducing a hemizygous mutation in said cell.
A method for producing a transgenic bovine having reduced expression of functional prion protein, said method comprising the steps of:
Dependencies are inferred from the claim text.